Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress - Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...